中国临床药理学杂志2018，Vol.34Issue(5)：497-500,4.DOI:10.13699/j.cnki.1001-6821.2018.05.003
噻托溴铵粉雾剂联合沙美特罗替卡松粉吸入剂治疗慢性阻塞性肺疾病急性加重期伴呼吸衰竭的临床研究
摘要
Abstract
Objective To observe the clinical efficacy and safety of tiotropium bromide powder inhalation combined with salmeterol xinafoate and fluticasone propionate powder inhalation in the treatment of acute exacerbation of chronic obstructive pulmonary disease (COPD) complicated with respiratory failure.Methods Seventy-six patients with acute exacerbation of COPD complicated with respiratory failure were randomly divided into control group and treatment group with 38 cases per group.Control group received routine treatment and ventilator-assisted ventilation treatment.Treatment group received salmeterol xinafoate and fluticasone propionate powder inhalation 1 suction,bid,inhalation treatment +tiotropium bromide powder inhalation 18 μg,qd,inhalation treatment,on the basis of control group.Two groups were treated for 2 weeks.The clinical efficacy,arterial blood gas indexes,procalcitonin,immune functions and adverse drug reactions were compared between two groups.Results After treatment,the total effective rates of treatment and control groups were 92.11％ (35 cases/38 cases) and 73.68％ (28 cases/38 cases) with significant difference (P ＜0.05).After treatment,the main indexes in treatment and control groups were compared:arterial partial pressure of oxygen were (86.35 ±7.04) and (77.49 ±6.85)mmHg,oxygenation index were (310.89 ±29.87) and (281.34 ±27.53)mmHg,procalcitonin were (1.42 ± 0.54) and (1.93 ± 0.61)ng · mL-1,tumor necrosis factor-α were (275.49 ±48.62) and (310.05 ±54.73)ng · L-1,interleukin-8 were (312.62 ±75.64) and (389.75 ±78.76)pg · mL-1,high sensitive C-reactive protein were (4.73 ±2.45) and (8.34 ±2.53)mg · L-1,the differences were statistically significant (all P ＜ 0.05).There were no adverse drug reactions in the two groups during the treatment.Conclusion Tiotropium bromide powder inhalation combined with salmeterol xinafoate and fluticasone propionate powder inhalation has a definitive clinical efficacy and safety in the treatment of acute exacerbation of COPD complicated with respiratory failure,which can significantly reduce the levels of procalcitonin,improve the blood gas indexes and immune function.关键词
噻托溴铵粉雾剂/沙美特罗替卡松粉吸入剂/慢性阻塞性肺疾病急性加重期/呼吸衰竭/安全性Key words
salmeterol xinafoate and fluticasone propionate powder inhalation/tiotropium bromide powder inhalation/acute exacerbation of chronic obstructive pulmonary disease/respiratory failure/safety分类
医药卫生引用本文复制引用
王发辉,石慧芳,林石宁,徐建光,何海武,王秋婷..噻托溴铵粉雾剂联合沙美特罗替卡松粉吸入剂治疗慢性阻塞性肺疾病急性加重期伴呼吸衰竭的临床研究[J].中国临床药理学杂志,2018,34(5):497-500,4.基金项目
海南省自然科学基金资助项目(2012-812172) （2012-812172）
